Cancer Treatment Centers of America (CTCA) recently began enrolling patients with cancer for the clinical trial study TAPUR — Targeted Agent and Profiling Utilization Registry.
A subunit of a signaling protein may be a new therapeutic target in multiple myeloma (MM), a hematologic malignancy with high relapse rates and resulting drug resistance in patients, according…
Researchers at The University of Texas MD Anderson Cancer Center, in collaboration with other institutions, identified a gene called TJP1 that could help predict which…
Takeda Pharmaceutical has published promising data from the TOURMALINE-MM1 Phase 3 clinical trial of patients with relapsed and/or refractory multiple myeloma (MM), treated with the combination…
